spacer
home > white papers > Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs - World Courier
WHITE PAPERS
logo_World_Cour5.JPEG

World Courier

phone +44 (0)20 7928 7256
email marketing@worldcourier.com
web http://www.worldcourier.com
email 12th Floor, 25 Farringdon Street, London, EC4A4AB

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Novo Nordisk Foundation Announces Support For New Open Collaborative Platform to Accelerate the Development of Plant-Based Foods

A new collaborative platform, Plant2Food, aims to accelerate the development of plant-based foods. Researchers and companies are invited to collaborate in exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking out patents based on the results. The Novo Nordisk Foundation is supporting the platform with up to €27 million over the next five years.
More info >>


White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement